Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

Sponsor

University of California, Los Angeles (Other)

Overall Status

Withdrawn

CT.gov ID

NCT02053727

Collaborator

(none)

Enrollment

Location

Arms

47.4

Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate whether the combination of abatacept along with entecavir (the study drugs) is safe and effective in treating symptoms related to rheumatoid arthritis (RA).

Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form, is approved by the FDA for the treatment of RA. In this research, abatacept will be given by injection. A subcutaneous injection is an injection given under the skin.

Entecavir, to be taken by mouth, is approved by the FDA for the treatment of hepatitis B.

The study is divided into the following time periods:

Screening Phase: Up to 4 weeks Randomized Double-blind Phase: 24 weeks Open-label Extension Phase: 24 weeksFollow-up Phase: a phone call after Week 48

Each phase contains one or more study visits.

Condition or Disease	Intervention/Treatment	Phase
Rheumatoid Arthritis Chronic Hepatitis B	Drug: Abatacept Drug: Placebo	N/A

Detailed Description

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder affecting 1% of the world's population. If not adequately controlled, it may lead to disability in up to 30% of patients within the first three years of disease onset [1] and can be associated with premature death. Recent research has suggested that the first event in the pathogenesis of RA is an antigen dependent activation of T-cells in an immunogenetically susceptible host. T-cells require two signals for activation, one involving the trimolecular complex (class II Major Histocompatibility Complex (MHC), antigen, T-cell receptor), and the other being co-stimulation of the CD28 (Cluster of Differentiation 28) molecule on T-cells by the B7 molecules (CD80 and CD86) on antigen presenting cells.

Hepatitis B virus (HBV) can cause chronic disease in 5% of immunocompetent adults and has a prevalence of over 350 million worldwide. It is a leading cause of chronic hepatitis, cirrhosis and hepatocellular cancer and accounts for one million deaths annually. In patients with chronic hepatitis B and RA, treatment options are limited. Traditional disease modifying anti-rheumatic drugs (DMARDs) are associated with hepatotoxicity and are contraindicated in chronic hepatitis. A recent retrospective analysis suggests that successful use of anti-tumor necrosis factor alpha (anti-TNF) agents may be possible in these patients but the authors do warn that these patients should be closely monitored and that fatal reactivation of hepatitis B is possible. Treatment with rituximab, a chimeric monoclonal antibody against B-cell protein CD20, is another option; however, the use of this medication in RA patients with chronic hepatitis B may also cause reactivation.

When RA patients with chronic hepatitis B were started on a Tumor Necrosis Factor (TNF) inhibitor or methotrexate (MTX), 2 of 5 HBsAg+ patients reactivated their hepatitis B, indicating a possible high rate of activation in these patients when not on hepatitis B treatment. Reactivation in this and another study occurred after 9-19 months of antirheumatic therapy. In RA patients with chronic Hepatitis B, entecavir appears to be effective at preventing reactivation.

There are no studies on the safety of abatacept in patients with RA and HBV. Adequate T-cell function is important to help cure or contain HBV infection. Our site has conducted a retrospective study that shows preliminary safety of abatacept in patients with RA and chronic Hepatitis B on antiviral therapy. The purpose of this study is to assess the safety and efficacy of abatacept in RA patients with chronic Hepatitis B in a pilot study in a randomized, controlled fashion.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial.

Study Start Date :

Jul 1, 2014

Actual Primary Completion Date :

Jun 12, 2018

Actual Study Completion Date :

Jun 12, 2018

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Abatacept Arm This arm of study subjects will receive 125 mg subcutaneous abatacept during the 24 week double blind period.	Drug: Abatacept Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept. Other Names: Orencia
Placebo Comparator: Placebo Arm This arm of study patients will receive matching placebo injections during the 24 week double blind period.	Drug: Placebo

Arm

Intervention/Treatment

Active Comparator: Abatacept Arm

This arm of study subjects will receive 125 mg subcutaneous abatacept during the 24 week double blind period.

Drug: Abatacept

Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.

Other Names:

Orencia

Placebo Comparator: Placebo Arm

This arm of study patients will receive matching placebo injections during the 24 week double blind period.

Drug: Placebo

Outcome Measures

Primary Outcome Measures

Number of Participants with Serious Adverse Events [Every 4 weeks from Week 4 to Week 48]
Adverse events will be assessed at timepoints specified in the protocol.
Number of Subjects with Hepatitis B Reactivation [Every 4 Weeks from Week 4 to Week 48]
Blood test for Hepatitis B Virus (HBV) DNA will be used.

Secondary Outcome Measures

DAS28-ESR-4 Unit [Screening, Weeks 4, 8, 12, 24, 36, and 48]
CDAI Unit [Screening, Weeks 4,8,12,24,36,48]
TJC Count [Screening, Weeks 4,8,12,24,36,48]
SJC Count [Screening, Weeks 4,8,12,24,36,48]
Patient Global (Visual Analogue Scale) [Screening, Weeks 4,8,12,24,36,48]
MD Global (Visual Analogue Scale) [Screening, Weeks 4,8,12,24,36,48]
Pain (measured on a 5 point Likert scale) [Screening, Weeks 4,8,12,24,36,48]
Global Assessment of Disease Activity (as measured on a 5 point Likert scale) [Screening, Weeks 4,8,12,24,36,48]
HAQ-DI Units [Screening, Weeks 4,8,12,24,36,48]
Fatigue (as assessed by FACIT-Fatigue Unit) [Screening, Weeks 4,8,12,24,36,48]
Sleep as assessed by Medical Outcomes Study Sleep Instrument Unit [Screening, Weeks 4,8,12,24,36,48]
ACR 20/50/70 Percentage [Screening, Weeks 4,8,12,24,36,48]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosis of RA.
Baseline CDAI >10 with TJC (Tender Joint Count) > 4 and SJC (Swollen Joint Count) > 2.
Chronic Hepatitis B as defined by a history of patients with a HBsAg positive for at least 6 months with undetectable HBV DNA; or a history of patients with negative HBsAg and positive HBcAb or HBsAb, with undetectable HBV DNA.
No evidence of hepatocellular carcinoma (HCC) based upon alpha-fetoprotein (AFP) ≤20 ng/mL at screening,) negative liver imaging as shown by ultrasound, computerized tomography or magnetic resonance imaging within 24 weeks of screening. Participants with AFP >20 ng/mL must be evaluated clinically with additional imaging and shown not to have HCC on CT or MRI before they can be enrolled.
Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) and NSAIDs (Non-Steroidal Anti-inflammatory Drugs) are permitted if the patient is on a stable dose regimen for ≥ 2 weeks prior to and including at baseline.
Men and women, >= 18 years of age.

Exclusion Criteria:

Women who are pregnant or breastfeeding. Sexually active fertile men not using effective birth control if their partners are WOCBP (Women of Child Bearing Potential).
Target Disease Exceptions

Rheumatic autoimmune disease other than RA; fibromyalgia or keratoconjunctivitis/xerostomia are allowed, as long as these will not confound the CLINICAL EFFICACY OUTCOMES.

Medical History and Concurrent Diseases
Subjects who are impaired, incapacitated, or incapable of completing study-related assessments.
Subjects who underwent previous MCP (metacarpophalangeal) arthroplasty, have such a procedure scheduled, or anticipate the need for such a procedure during the study.
Major surgery (including joint surgery) within 8 weeks prior to screening
Subjects with active vasculitis of a major organ system, with the exception of rheumatoid nodules or minor rheumatoid vasculitis lesions of the skin
Subjects with current uncontrolled symptoms of severe, progressive, or uncontrolled renal, hepatic hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, including Cirrhosis with Child-Pugh Class >=2 or COPD (chronic obstructive pulmonary disease) with FEV1 (forced expiratory volume in 1 second) /FVC (forced vital capacity) < 0.6
Female subjects who have had a recent breast cancer screening that is suspicious for malignancy and where the diagnosis is not excluded.

Subjects who currently abuse drugs or alcohol. i) Subjects with evidence of active or latent bacterial or viral infections at the time of potential enrollment, including HIV.
Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed.
Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication.
Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection.
Subjects at risk for tuberculosis (TB) or not treated for latent TB is tested positive.
Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.
Subjects who have abnormal laboratory values

Prohibited Treatments and/or Therapies
Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose.
Any concomitant biologic DMARD, such as anakinra.
Previous treatment with cell-depleting therapies, including investigational agents, including but not limited to CAMPATH, anti-CD4 (cluster of differentiation 4), anti-CD5, anti-CD3, and anti-CD19.
Anti-CD20 treatment within the last 6 months (OK to include if they were dosed > 6 months ago).
Treatment with methotrexate, hydroxychloroquine, cyclosporine A, azathioprine, mycophenolate mofetil, within <= 4 weeks prior to baseline.
Treatment with etanercept within 2 weeks, infliximab/certolizumab/golimumab/adalimumab with <=8 weeks, anakinra within <=1 week prior to baseline.
Previous abatacept use.
Treatment with sulfasalazine within < 4 weeks prior to baseline